{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:05:40Z","timestamp":1761523540688,"version":"3.40.4"},"reference-count":22,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2005]]},"abstract":"<jats:p>&lt;i&gt;Objectives:&lt;\/i&gt; Colorectal cancer is usually diagnosed in elderly patients. Since there is clear evidence that such patients are under-treated and under-represented or even excluded from clinical studies and there are no reliable and prospective data on the feasibility and efficacy of an oxaliplatin (L-OHP)-based chemotherapy in this setting, we have tested the L-OHP plus oral uracil\/tegafur (UFT) and oral folinic acid (FA) combination as first-line therapy in patients with advanced or metastatic colorectal cancer (MCRC) aged 70 or older. &lt;i&gt;Patients and Methods:&lt;\/i&gt; Forty-seven patients with advanced or MCRC, aged over 70, were treated with L-OHP 65 mg\/m&lt;sup&gt;2&lt;\/sup&gt; as an intravenous 3-hour infusion on day 1 and 8 plus UFT 300 mg\/m&lt;sup&gt;2&lt;\/sup&gt; and FA 90 mg in 3 divided doses given orally on days 1\u201314 for each 3-week cycle. Patients were followed by a geriatric and a quality of life (QoL) assessment with specific scales and EORTC-QLQ-C30 questionnaire. &lt;i&gt;Results:&lt;\/i&gt; All patients were assessable for toxicity and 45 for response to treatment. Complete response was achieved in 2 patients (4%) and partial response in 22 (47%) [overall response rate, 51%; 95% confidence interval (CI): 40.7\u201361.2%]; 18 patients (38%) had stable disease, and 5 (11%) had disease progression. The median duration of response was 8 months (range, 3\u201319+ months). After a minimum follow-up of 17 months, the median time to disease progression and the median overall survival were 8.0 (95% CI: 6.7\u20139.3%) and 14.1 (95% CI: 11.0\u201317.1%) months, respectively. Regimen safety was manageable. Most adverse events were mild to moderate, and this did not result in QoL impairment. The most common grade 3\u20134 treatment-related adverse events were diarrhea (17%), neutro- and thrombocytopenia (2%), laryngeal spasm (2%), and peripheral neuropathy (12.7%). No treatment-related deaths occurred. &lt;i&gt;Conclusions:&lt;\/i&gt; These results confirmed that this tested chemotherapy combination is active with acceptable tolerability and QoL maintenance in elderly patients with advanced or MCRC.<\/jats:p>","DOI":"10.1159\/000087814","type":"journal-article","created":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T09:55:16Z","timestamp":1124877316000},"page":"122-129","source":"Crossref","is-referenced-by-count":38,"title":["Phase II Trial of Oxaliplatin and Tegafur\/Uracil and Oral Folinic Acid for Advanced or Metastatic Colorectal Cancer in Elderly Patients"],"prefix":"10.1159","volume":"69","author":[{"given":"Gerardo","family":"Rosati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cordio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Manzione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2005,9,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1011170808734"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2898%2902309-5"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2898%2903085-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM200009283431302"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2800%2902034-1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2004.09.046"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2002.04.123"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2002.10.129"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1011115207518"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1008397109048"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159%2F000079485"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819810101%2947%3A1%3C207%3A%3AAID-CNCR2820470134%3E3.0.CO%3B2-6"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F85.5.365"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2F0197-2456%2889%2990015-9"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2307%2F2281868"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.11110"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2004.11.069"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1008213732429"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6601310"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097%2F00000421-200204000-00005"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097%2F00004836-200303000-00009"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2004.11.037"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/87814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/87814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:25:21Z","timestamp":1745465121000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000087814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000087814","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2005]]}}}